Search

Search Constraints

You searched for: Author/Creator Gilletta, C

Search Results

1. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study. (21st January 2022)

2. OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE). (21st January 2022)

3. OP24 Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease. (25th January 2019)

4. P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients. (21st January 2022)

5. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission. (30th January 2023)

6. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study. (30th January 2023)

7. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study. (27th May 2021)

8. P593 Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study. (16th January 2018)

9. P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study. (21st January 2022)

10. P638 Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study. (30th January 2023)